image credit: Freepik

Nexcella Begins Production of CAR-T Cell Therapy Engineering Batches at US Manufacturing Site

Nexcella, a subsidiary of US-based Immix Biopharma and a clinical-stage biopharmaceutical company, announced on May 26, 2023 that it has begun producing engineering batches of NXC-201, its lead candidate and a chimeric antigen receptor T cell (CAR-T) therapy, at its US manufacturing site.

These engineering batches are intended to support the company’s planned expansion into the United States of an ongoing Phase Ib/IIa clinical study (NEXICART-1 [NCT04720313]) in adults with relapsed or refractory multiple myeloma and amyloid light chain (AL) amyloidosis. NXC-201 is a novel B-cell maturation antigen (BCMA)-targeted CAR-T cell therapy. The commencement of these engineering batches represents a crucial next step in transferring Nexcella’s existing CAR-T good manufacturing practice manufacturing process to the US, according to a company press release.

Read More on Biopharm International